TY  - JOUR
T1  - Dual Facets of Wnt/β-Catenin Signaling in Hepatocellular Carcinoma: Implications for Tumor Phenotyping and Clinical Management
A1  - R. Gomez
A1  - M. Sanchez
A1  - E. Lopez
JF  - Asian Journal of Current Research in Clinical Cancer
JO  - Asian J Curr Res Clin Cancer
SN  - 3062-4444
Y1  - 2023
VL  - 3
IS  - 1
DO  - 10.51847/7icRlMe63L
SP  - 84
EP  - 95
N2  - The combination of immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor (VEGF) inhibitors has become a standard first-line therapy for patients with unresectable hepatocellular carcinoma (HCC), highlighting the importance of ICIs in treatment strategies. However, around one-fifth of patients fail to respond, often due to activating mutations in the Wnt/β-catenin signaling pathway, which are associated with primary resistance. Detecting Wnt/β-catenin activation through non-invasive methods could therefore be crucial for guiding clinical management in advanced HCC. Mutations in this pathway manifest in two distinct tumor behaviors: the “Jekyll phenotype,” which shows limited vascular invasion, low metastatic potential, and favorable prognosis, and the “Hyde phenotype,” a more aggressive form characterized by poor differentiation, frequent metastasis, cancer stem cell characteristics, and elevated serum alpha-fetoprotein levels. Differentiation between these phenotypes may be achieved using a combination of hepatobiliary phase Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI), which highlights the Jekyll phenotype via increased nodule enhancement, and FDG-PET/CT, which identifies the Hyde phenotype through elevated glucose uptake.
UR  - https://galaxypub.co/article/dual-facets-of-wntb-catenin-signaling-in-hepatocellular-carcinoma-implications-for-tumor-phenotypi-synv3vwbgltb2iv
ER  -